Decline in infection-related morbidities following drug-mediated reductions in the intensity of Schistosoma infection: A systematic review and meta-analysis

PLoS Neglected Tropical Diseases

Volumn 11, Issue 2, 2017, Pages

  Andrade, Gisele ^a   Bertsch, David J ^b   Gazzinelli, Andrea ^a,c   King, Charles H ^b,d  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Instituto Nacional de Ciencia e Tecnologia em Doencas Tropicais INCT DT   (Brazil)

^d UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYCANTHONE; METRIFONATE; OXAMNIQUINE; PRAZIQUANTEL; ANTHELMINTIC AGENT;

ARTICLE; DIARRHEA; DISPERSITY; ECHOGRAPHY; FECES ANALYSIS; HEPATOMEGALY; HUMAN; HYPERTENSION; INFECTION RATE; INTERVENTION STUDY; LIVER FIBROSIS; META ANALYSIS; MORBIDITY; NONHUMAN; PARASITE IDENTIFICATION; PORTAL VEIN; PREVALENCE; SCHISTOSOMA HAEMATOBIUM; SCHISTOSOMA JAPONICUM; SCHISTOSOMIASIS; SCHISTOSOMIASIS MANSONI; SPLENOMEGALY; SYSTEMATIC REVIEW (TOPIC); TISSUE INJURY; UROGENITAL TRACT INFECTION; ANIMAL; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; MORTALITY; PARASITOLOGY; PHYSIOLOGY; SCHISTOSOMA;

ANIMALS; ANTHELMINTICS; HUMANS; PRAZIQUANTEL; SCHISTOSOMA; SCHISTOSOMIASIS;

EID: 85014456395     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0005372     Document Type: Article

References (50)

1. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J, Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis. 2006;6(7):411–425. doi: 10.1016/S1473-3099(06)70521-716790382
2. King CH, Dangerfield-Cha M, The unacknowledged impact of chronic schistosomiasis. Chronic Illness. 2008;4:65–79. doi: 10.1177/174239530708440718322031
3. Burke ML, Jones MK, Gobert GN, Li YS, Ellis MK, McManus DP, Immunopathogenesis of human schistosomiasis. Parasite Immunol. 2009;31(4):163–176. doi: 10.1111/j.1365-3024.2009.01098.x19292768
4. Fairfax K, Nascimento M, Huang SC, Everts B, Pearce EJ, Th2 responses in schistosomiasis. Semin Immunopathol. 2012;34(6):863–871. doi: 10.1007/s00281-012-0354-423139101
5. Booth M, Guyatt HL, Li Y, Tanner M, The morbidity attributable to Schistosoma japonicum infection in 3 villages in Dongting Lake region, Hunan province, PR China. Trop Med Int Health. 1996;1(5):646–654. 8911449
6. Booth M, Vennervald BJ, Kabatereine NB, Kazibwe F, Ouma JH, Kariuki CH, et al. Hepatosplenic morbidity in two neighbouring communities in Uganda with high levels of Schistosoma mansoni infection but very different durations of residence. Trans R Soc Trop Med Hyg. 2004;98(2):125–136. 14964813
7. Richter J, The impact of chemotherapy on morbidity due to schistosomiasis. Acta Trop. 2003;86(2–3):161–183. Epub 2003/05/15. 12745135
8. King CH, Dickman K, Tisch DJ, Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet. 2005;365:1561–1569. doi: 10.1016/S0140-6736(05)66457-415866310
9. King CH, Toward the elimination of schistosomiasis. N Engl J Med. 2009;360(2):106–109. doi: 10.1056/NEJMp080804119129524
10. WHOPrevention and control of schistosomiasis and soil-transmitted helminthiasis: report of a WHO expert committee. Technical Report Series 912. Geneva: World Health Organization, 2002 912.
11. Brouwer KC, Ndhlovu PD, Wagatsuma Y, Munatsi A, Shiff CJ, Epidemiological assessment of Schistosoma haematobium-induced kidney and bladder pathology in rural Zimbabwe. Acta Trop. 2003;85(3):339–347. 12659971
12. Kahama AI, Vennervald BJ, Kombe Y, Kihara RW, Ndzovu M, Mungai P, et al. Parameters associated with Schistosoma haematobium infection before and after chemotherapy in school children from two villages in the coast province of Kenya. Trop Med Int Health. 1999;4(5):335–340. 10402968
13. Leenstra T, Acosta LP, Langdon GC, Manalo DL, Su L, Olveda RM, et al. Schistosomiasis japonica, anemia, and iron status in children, adolescents, and young adults in Leyte, Philippines Am J Clin Nutr. 2006;83(2):371–379. 16469997
14. Wamachi AN, Mayadev JS, Mungai PL, Magak PL, Ouma JH, Magambo JK, et al. Increased ratio of tumor necrosis factor-alpha to interleukin-10 production is associated with Schistosoma haematobium-induced urinary-tract morbidity. J Infect Dis. 2004;190(11):2020–2030. doi: 10.1086/42557915529268
15. Koukounari A, Gabrielli AF, Toure S, Bosque-Oliva E, Zhang Y, Sellin B, et al. Schistosoma haematobium infection and morbidity before and after large-scale administration of praziquantel in Burkina Faso. J Infect Dis. 2007;196(5):659–669. doi: 10.1086/52051517674306
16. Leenstra T, Coutinho HM, Acosta LP, Langdon GC, Su L, Olveda RM, et al. Schistosoma japonicum reinfection after praziquantel treatment causes anemia associated with inflammation. Infect Immun. 2006;74(11):6398–6407. doi: 10.1128/IAI.00757-0616923790
17. Carlton EJ, Hsiang M, Zhang Y, Johnson S, Hubbard A, Spear RC, The impact of Schistosoma japonicum infection and treatment on ultrasound-detectable morbidity: a five-year cohort study in Southwest China. PLoS Negl Trop Dis. 2010;4(5):e685. doi: 10.1371/journal.pntd.000068520502515
18. Koukounari A, Donnelly CA, Sacko M, Keita AD, Landoure A, Dembele R, et al. The impact of single versus mixed schistosome species infections on liver, spleen and bladder morbidity within Malian children pre- and post-praziquantel treatment. BMC Infect Dis. 2010;10:227. doi: 10.1186/1471-2334-10-22720670408
19. Webster JP, Koukounari A, Lamberton PH, Stothard JR, Fenwick A, Evaluation and application of potential schistosome-associated morbidity markers within large-scale mass chemotherapy programmes. Parasitology. 2009;136(13):1789–1799. doi: 10.1017/S003118200900635019523252
20. Coutinho HM, Acosta LP, McGarvey ST, Jarilla B, Jiz M, Pablo A, et al. Nutritional status improves after treatment of Schistosoma japonicum-infected children and adolescents. J Nutr. 2006;136(1):183–188. 16365080
21. Kabatereine NB, Brooker S, Koukounari A, Kazibwe F, Tukahebwa EM, Fleming FM, et al. Impact of a national helminth control programme on infection and morbidity in Ugandan schoolchildren. Bull World Health Organ. 2007;85(2):91–99. doi: 10.2471/BLT.06.03035317308729
22. Stephenson LS, Latham MC, Kinoti SN, Oduori ML, Regression of splenomegaly and hepatomegaly in children treated for Schistosoma haematobium infection. Am J Trop Med Hyg. 1985;34(1):119–123. 3970303
23. Doehring E, Ehrich JHH, Bremer HJ, Reversibility of urinary tract abnormalities due to Schistosoma haematobium infection. Kidney International. 1986;30:582–585. 3097374
24. Homeida MA, el Tom I, Nash T, Bennett JL, Association of the therapeutic activity of praziquantel with the reversal of Symmers' fibrosis induced by Schistosoma mansoni. Am J Trop Med Hyg. 1991;45(3):360–365. 1928571
25. King CH, Lombardi G, Lombardi C, Greenblatt R, Hodder S, Kinyanjui H, et al. Chemotherapy-based control of schistosomiasis haematobia. II. Metrifonate vs. praziquantel in control of infection-associated morbidity. Am J Trop Med Hyg. 1990;42(6):587–595. 2115308
26. Li YS, Sleigh AC, Li Y, Tanner M, Dessein A, Williams GM, et al. Five-year impact of repeated praziquantel treatment on subclinical morbidity due to Schistosoma japonicum in China. Trans R Soc Trop Med Hyg. 2002;96(4):438–443. 12497984
27. Cota GF, Pinto-Silva RA, Antunes CM, Lambertucci JR, Ultrasound and clinical investigation of hepatosplenic schistosomiasis: evaluation of splenomegaly and liver fibrosis four years after mass chemotherapy with oxamniquine. Am J Trop Med Hyg. 2006;74(1):103–107. 16407352
28. WHOSchistosomiasis and soil-transmitted helminthiases: number of people treated in 2015. Wkly Epidemiol Rec. 2016;91(49–50):585–595. 27934297
29. WHOSchistosomiasis: progress report 2001–2011, strategic plan 2012–2020. Geneva: World Health Organization, 2013.
30. Olliaro PL, Vaillant M, Diawara A, Coulibaly JT, Garba A, Keiser J, et al. Toward measuring Schistosoma response to praziquantel treatment with appropriate descriptors of egg excretion. PLoS Negl Trop Dis. 2015;9(6):e0003821. doi: 10.1371/journal.pntd.000382126086551
31. Koukounari A, Hollingsworth TD, A strengthening evidence-base for mass deworming, but questions remain. Lancet. 2016.
32. Egger M, Davey-Smith G, Altman DG, Systematic Reviews in Health Care: Meta-analysis in Context. Somerset, N.J.: John Wiley & Sons; 2008.
33. Higgins JP, Thompson SG, Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558. Epub 2002/07/12. doi: 10.1002/sim.118612111919
34. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–2012. 10789670
35. Gryseels B, Nkulikyinka L, Engels D, Impact of repeated community-based selective chemotherapy on morbidity due to schistosomiasis mansoni. Am J Trop Med Hyg. 1994;51(5):634–641. 7985756
36. Zhao G, Jiang Q, Wasley A, Zhang S, ljWu Z, Liu Z, et al. Changes in prevalence, intensity of infection and morbidity due to Schistosoma japonicum infection in a community following a single treatment with praziquantel. Trop Geogr Med. 1995;47(6):289–292. 8650742
37. Betson M, Sousa-Figueiredo JC, Kabatereine NB, Stothard JR, Use of fecal occult blood tests as epidemiologic indicators of morbidity associated with intestinal schistosomiasis during preventive chemotherapy in young children. Am J Trop Med Hyg. 2012;87(4):694–700. doi: 10.4269/ajtmh.2012.12-005922927499
38. Stephenson LS, Latham MC, Kurz KM, Kinoti SN, Oduori ML, Crompton DW, Relationships of Schistosoma haematobium, hookworm and malarial infections and metrifonate treatment to growth of Kenyan school children. Am J Trop Med Hyg. 1985;34(6):1109–1018. 3938925
39. Beasley NM, Tomkins AM, Hall A, Kihamia CM, Lorri W, Nduma B, et al. The impact of population level deworming on the haemoglobin levels of schoolchildren in Tanga, Tanzania. Trop Med Int Health. 1999;4(11):744–750. 10588768
40. Emukah E, Gutman J, Eguagie J, Miri ES, Yinkore P, Okocha N, et al. Urine heme dipsticks are useful in monitoring the impact of praziquantel treatment on Schistosoma haematobium in sentinel communities of Delta State, Nigeria. Acta Trop. 2012;122(1):126–131. doi: 10.1016/j.actatropica.2012.01.00222245148
41. Lengeler C, Utzinger J, Tanner M, Screening for schistosomiasis with questionnaires. Trends Parasitol. 2002;18(9):375–377. 12377245
42. Hatz CF, Vennervald BJ, Nkulila T, Vounatsou P, Kombe Y, Mayombana C, et al. Evolution of Schistosoma haematobium-related pathology over 24 months after treatment with praziquantel among school children in southeastern Tanzania. Am J Trop Med Hyg. 1998;59(5):775–781. 9840596
43. King CH, Ultrasound monitoring of structural urinary tract disease in S. haematobium infection. Memorias do Instituto Oswaldo Cruz. 2002;97 (Suppl. 1):149–152.
44. Magak P, Chang-Cojulun A, Kadzo H, Ireri E, Muchiri E, Kitron U, et al. Case-control study of posttreatment regression of urinary tract morbidity among adults in Schistosoma haematobium-endemic communities in Kwale County, Kenya. Am J Trop Med Hyg. 2015;93(2):371–376. doi: 10.4269/ajtmh.15-015326013375
45. Richter J, Evolution of schistosomiasis-induced pathology after therapy and interruption of exposure to schistosomes: a review of ultrasonographic studies. Acta Trop. 2000;77(1):111–131. 10996127
46. Lambertucci JR, Revisiting the concept of hepatosplenic schistosomiasis and its challenges using traditional and new tools. Rev Soc Bras Med Trop. 2014;47(2):130–136. 24861284
47. Richter J, Correia Dacal AR, Vergetti Siqueira JG, Poggensee G, Mannsmann U, Deelder A, et al. Sonographic prediction of variceal bleeding in patients with liver fibrosis due to Schistosoma mansoni. Trop Med Int Health. 1998;3:728–735. 9754668
48. Smith JH, Christie JD, The pathobiology of Schistosoma haematobium infection in humans. Hum Pathol. 1986;17:333–345. 3082740
49. Chen MG, Mott KE, Progress in assessment of morbidity due to Schistosoma haematobium infection. Trop Dis Bull. 1989;86:R1–36.
50. Cao J, Liu WJ, Xu XY, Zou XP, Endoscopic findings and clinicopathologic characteristics of colonic schistosomiasis: a report of 46 cases. World J Gastroenterol. 2010;16(6):723–727. doi: 10.3748/wjg.v16.i6.72320135720